Replies to post #23199 on Elite Swing Trades

[oldberkeley]

RNA: Now that RNA's partnership with GSK is over and more importantly GSK is out of the decision-making process, I wouldn't be surprised if Sarepta (SRPT) buys them out for a decent premium, especially considering the current ridiculously low valuation.